vs
GLOBUS MEDICAL INC（GMED）与泰利福（TFX）财务数据对比。点击上方公司名可切换其他公司
泰利福净利率更高（177.8% vs 17.0%，领先160.7%）。GLOBUS MEDICAL INC同比增速更快（25.7% vs -150.5%）。GLOBUS MEDICAL INC自由现金流更多（$202.4M vs $-92.9M）。过去两年泰利福的营收复合增速更高（NaN% vs NaN%）
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
泰利福（Teleflex）总部位于美国宾夕法尼亚州韦恩，是专业医疗设备供应商，产品广泛应用于重症监护、外科手术等各类诊疗场景。公司年营收达24亿美元，在全球40个国家开展业务，员工总数超15000人。经过数年的收并购与业务剥离，公司于2011年完成业务调整，全面聚焦医疗设备制造领域。
GMED vs TFX — 直观对比
营收规模更大
GMED
是对方的-2.1倍
$-401.9M
营收增速更快
GMED
高出176.3%
-150.5%
净利率更高
TFX
高出160.7%
17.0%
自由现金流更多
GMED
多$295.3M
$-92.9M
两年增速更快
TFX
近两年复合增速
16.7%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $826.4M | $-401.9M |
| 净利润 | $140.6M | $-714.3M |
| 毛利率 | 68.4% | — |
| 营业利润率 | 20.5% | — |
| 净利率 | 17.0% | 177.8% |
| 营收同比 | 25.7% | -150.5% |
| 净利润同比 | 430.4% | -422.7% |
| 每股收益（稀释后） | $1.01 | $-15.85 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMEDTFX
| Q4 25 | $826.4M | $-401.9M | ||
| Q3 25 | $769.0M | $913.0M | ||
| Q2 25 | $745.3M | $780.9M | ||
| Q1 25 | $598.1M | $700.7M | ||
| Q4 24 | $657.3M | $795.4M | ||
| Q3 24 | $625.7M | $764.4M | ||
| Q2 24 | $629.7M | $749.7M | ||
| Q1 24 | $606.7M | $737.8M |
净利润GMEDTFX
| Q4 25 | $140.6M | $-714.3M | ||
| Q3 25 | $119.0M | $-408.9M | ||
| Q2 25 | $202.8M | $122.6M | ||
| Q1 25 | $75.5M | $95.0M | ||
| Q4 24 | $26.5M | $-136.7M | ||
| Q3 24 | $51.8M | $111.0M | ||
| Q2 24 | $31.8M | $80.0M | ||
| Q1 24 | $-7.1M | $15.3M |
毛利率GMEDTFX
| Q4 25 | 68.4% | — | ||
| Q3 25 | 67.2% | 49.5% | ||
| Q2 25 | 66.6% | 55.2% | ||
| Q1 25 | 67.3% | 55.6% | ||
| Q4 24 | 59.9% | 55.3% | ||
| Q3 24 | 56.8% | 56.3% | ||
| Q2 24 | 58.7% | 55.6% | ||
| Q1 24 | 60.2% | 56.4% |
营业利润率GMEDTFX
| Q4 25 | 20.5% | — | ||
| Q3 25 | 17.9% | -44.8% | ||
| Q2 25 | 10.2% | 19.9% | ||
| Q1 25 | 16.2% | 17.9% | ||
| Q4 24 | 9.2% | -13.9% | ||
| Q3 24 | 7.7% | 19.5% | ||
| Q2 24 | 7.9% | 15.6% | ||
| Q1 24 | 1.3% | -0.6% |
净利率GMEDTFX
| Q4 25 | 17.0% | 177.8% | ||
| Q3 25 | 15.5% | -44.8% | ||
| Q2 25 | 27.2% | 15.7% | ||
| Q1 25 | 12.6% | 13.6% | ||
| Q4 24 | 4.0% | -17.2% | ||
| Q3 24 | 8.3% | 14.5% | ||
| Q2 24 | 5.0% | 10.7% | ||
| Q1 24 | -1.2% | 2.1% |
每股收益（稀释后）GMEDTFX
| Q4 25 | $1.01 | $-15.85 | ||
| Q3 25 | $0.88 | $-9.24 | ||
| Q2 25 | $1.49 | $2.77 | ||
| Q1 25 | $0.54 | $2.07 | ||
| Q4 24 | $0.19 | $-2.89 | ||
| Q3 24 | $0.38 | $2.36 | ||
| Q2 24 | $0.23 | $1.69 | ||
| Q1 24 | $-0.05 | $0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $557.2M | $378.6M |
| 总债务越低越好 | — | $2.6B |
| 股东权益账面价值 | $4.6B | $3.1B |
| 总资产 | $5.3B | $6.9B |
| 负债/权益比越低杠杆越低 | — | 0.85× |
8季度趋势，按日历期对齐
现金及短期投资GMEDTFX
| Q4 25 | $557.2M | $378.6M | ||
| Q3 25 | $18.8M | $354.0M | ||
| Q2 25 | — | $253.7M | ||
| Q1 25 | — | $284.1M | ||
| Q4 24 | $890.1M | $290.2M | ||
| Q3 24 | $71.9M | $243.2M | ||
| Q2 24 | $82.5M | $238.6M | ||
| Q1 24 | $80.4M | $237.4M |
总债务GMEDTFX
| Q4 25 | — | $2.6B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GMEDTFX
| Q4 25 | $4.6B | $3.1B | ||
| Q3 25 | $4.4B | $3.8B | ||
| Q2 25 | $4.3B | $4.2B | ||
| Q1 25 | $4.1B | $4.1B | ||
| Q4 24 | $4.2B | $4.3B | ||
| Q3 24 | $4.1B | $4.5B | ||
| Q2 24 | $4.0B | $4.6B | ||
| Q1 24 | $3.9B | $4.5B |
总资产GMEDTFX
| Q4 25 | $5.3B | $6.9B | ||
| Q3 25 | $5.1B | $7.9B | ||
| Q2 25 | $5.0B | $7.4B | ||
| Q1 25 | $4.7B | $7.2B | ||
| Q4 24 | $5.3B | $7.1B | ||
| Q3 24 | $5.1B | $7.5B | ||
| Q2 24 | $5.0B | $7.4B | ||
| Q1 24 | $4.9B | $7.5B |
负债/权益比GMEDTFX
| Q4 25 | — | 0.85× | ||
| Q3 25 | — | 0.70× | ||
| Q2 25 | — | 0.45× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.39× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $248.6M | $-92.3M |
| 自由现金流经营现金流 - 资本支出 | $202.4M | $-92.9M |
| 自由现金流率自由现金流/营收 | 24.5% | 23.1% |
| 资本支出强度资本支出/营收 | 5.6% | -0.2% |
| 现金转化率经营现金流/净利润 | 1.77× | — |
| 过去12个月自由现金流最近4个季度 | $588.8M | $1.4M |
8季度趋势，按日历期对齐
经营现金流GMEDTFX
| Q4 25 | $248.6M | $-92.3M | ||
| Q3 25 | $249.7M | $107.8M | ||
| Q2 25 | $77.9M | $7.8M | ||
| Q1 25 | $177.3M | $73.3M | ||
| Q4 24 | $210.3M | $202.6M | ||
| Q3 24 | $203.7M | $231.1M | ||
| Q2 24 | $54.3M | $91.7M | ||
| Q1 24 | $52.4M | $112.8M |
自由现金流GMEDTFX
| Q4 25 | $202.4M | $-92.9M | ||
| Q3 25 | $213.9M | $77.8M | ||
| Q2 25 | $31.3M | $-26.8M | ||
| Q1 25 | $141.2M | $43.3M | ||
| Q4 24 | $193.2M | $170.6M | ||
| Q3 24 | $161.7M | $209.9M | ||
| Q2 24 | $26.5M | $56.9M | ||
| Q1 24 | $23.8M | $74.4M |
自由现金流率GMEDTFX
| Q4 25 | 24.5% | 23.1% | ||
| Q3 25 | 27.8% | 8.5% | ||
| Q2 25 | 4.2% | -3.4% | ||
| Q1 25 | 23.6% | 6.2% | ||
| Q4 24 | 29.4% | 21.4% | ||
| Q3 24 | 25.8% | 27.5% | ||
| Q2 24 | 4.2% | 7.6% | ||
| Q1 24 | 3.9% | 10.1% |
资本支出强度GMEDTFX
| Q4 25 | 5.6% | -0.2% | ||
| Q3 25 | 4.7% | 3.3% | ||
| Q2 25 | 6.2% | 4.4% | ||
| Q1 25 | 6.0% | 4.3% | ||
| Q4 24 | 2.6% | 4.0% | ||
| Q3 24 | 6.7% | 2.8% | ||
| Q2 24 | 4.4% | 4.6% | ||
| Q1 24 | 4.7% | 5.2% |
现金转化率GMEDTFX
| Q4 25 | 1.77× | — | ||
| Q3 25 | 2.10× | — | ||
| Q2 25 | 0.38× | 0.06× | ||
| Q1 25 | 2.35× | 0.77× | ||
| Q4 24 | 7.94× | — | ||
| Q3 24 | 3.93× | 2.08× | ||
| Q2 24 | 1.71× | 1.15× | ||
| Q1 24 | — | 7.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
TFX
暂无分部数据
